Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
7 enrolled 14 charts
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
Phase 2 Completed
20 enrolled 13 charts
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Phase 2 Terminated
77 enrolled 18 charts
MK-1454-002
Phase 2 Completed
18 enrolled 14 charts
PAVO
Phase 2 Terminated
22 enrolled 17 charts
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Phase 4 Completed
81 enrolled 15 charts
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Completed
260 enrolled 52 charts
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
Phase 1 Terminated
3 enrolled 9 charts
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Phase 1/2 Terminated
87 enrolled 29 charts
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Phase 2 Terminated
54 enrolled 11 charts
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Phase 1/2 Terminated
222 enrolled 49 charts
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Phase 1/2 Terminated
3 enrolled 6 charts
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
37 enrolled 32 charts
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Phase 1/2 Terminated
41 enrolled 18 charts
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
109 enrolled 25 charts
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Phase 1 Terminated
14 enrolled 20 charts
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Phase 1 Completed
14 enrolled 13 charts
Parsabiv-MBD
Phase 2 Completed
22 enrolled 14 charts
HNSCC
Phase 2 Terminated
8 enrolled 8 charts
REVEAL
Phase 1/2 Terminated
64 enrolled 22 charts
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Phase 1 Completed
13 enrolled 10 charts
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Phase 2 Completed
52 enrolled 17 charts
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
Phase 1/2 Completed
35 enrolled 25 charts
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Phase 1 Completed
174 enrolled 68 charts
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Phase 1/2 Terminated
10 enrolled 14 charts
A Study of AK-01 (LY3295668) in Solid Tumors
Phase 1/2 Completed
13 enrolled 17 charts
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Phase 1 Completed
168 enrolled 59 charts
EXTAX
Phase 2 Terminated
17 enrolled 8 charts
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
Phase 2 Completed
14 enrolled 17 charts
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Phase 2 Completed
36 enrolled 24 charts
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Phase 2 Completed
33 enrolled 22 charts
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Phase 2 Terminated
157 enrolled 22 charts
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
Phase 2 Terminated
1 enrolled 6 charts
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
Phase 2 Terminated
21 enrolled 8 charts
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
Phase 1/2 Completed
12 enrolled 19 charts
TPEx
Phase 2 Completed
54 enrolled 9 charts
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
Phase NA Completed
24 enrolled 8 charts
Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436
Phase NA Completed
10 enrolled 9 charts
TOP
Completed
761 enrolled 17 charts
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Phase 1 Completed
26 enrolled 13 charts
S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
Phase 2 Completed
67 enrolled 10 charts